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Abstract
Background: Principal component analysis (PCA) and partial least square (PLS) regression may
be useful to summarize the HIV genotypic information. Without pre-selection each mutation
presented in at least one patient is considered with a different weight. We compared these two
strategies with the construction of a usual genotypic score.
Methods: We used data from the ANRS-CO3 Aquitaine Cohort Zephir sub-study. We used a
subset of 87 patients with a complete baseline genotype and plasma HIV-1 RNA available at baseline
and at week 12. PCA and PLS components were determined with all mutations that had
prevalences >0. For the genotypic score, mutations were selected in two steps: 1) p-value < 0.01
in univariable analysis and prevalences between 10% and 90% and 2) backwards selection
procedure based on the Cochran-Armitage Test. The predictive performances were compared by
means of the cross-validated area under the receiver operating curve (AUC).
Results: Virological failure was observed in 46 (53%) patients at week 12. Principal components
and PLS components showed a good performance for the prediction of virological response in HIV
infected patients. The cross-validated AUCs for the PCA, PLS and genotypic score were 0.880,
0.868 and 0.863, respectively. The strength of the effect of each mutation could be considered
through PCA and PLS components. In contrast, each selected mutation contributes with the same
weight for the calculation of the genotypic score. Furthermore, PCA and PLS regression helped to
describe mutation clusters (e.g. 10, 46, 90).
Conclusion: In this dataset, PCA and PLS showed a good performance but their predictive ability
was not clinically superior to that of the genotypic score.
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Background
The development of HIV resistance mutations is one of
the major problems for optimizing treatment of HIV-
infected patients. Therefore, resistance testing before start-
ing highly active antiretroviral therapy (HAART) or before
switching to a new antiretroviral component is widely rec-
ommended [1-4] and now routinely implemented in
industrialised countries. Resistance is due to mutations in
the viral genome, e.g. mutations in the reverse tran-
scriptase (RT), protease or integrase genes that cause
resistance to nucleoside RT inhibitors (NRTIs) and non-
nucleoside RT Inhibitors (NNRTIs), protease inhibitors
(PIs), or integrase inhibitors, respectively. Genotypic and
phenotypic resistance testing are the two commonly used
tests. The impact of genotypic mutations on virological
response in patients treated with a particular drug regimen
are based on in vitro informations or on the virological
response reported in patients who switched to that partic-
ular regimen. Before the initiation of an optimized treat-
ment, a genotype of the main (major) patients' virus
populations (only virus species present at >20–30% are
detected and therefore analysed) is assessed. Statistical
analyses aim at finding the baseline genotypic mutations
associated with virological response in order to predict
whether a patient who will switch to a similar regimen is
resistant or not. Noteworthy, data are mostly analysed for
the main drug of a given regimen only, i.e. NNRTI and/or
PI.
However, traditional statistical analyses of the association
between genotypic mutations and virological response are
hampered by i) the high number of potential mutations,
ii) the correlations between mutations and iii) the low
number of patients usually available for this type of study.
Specifically, the analysis of the effect of high number of
mutations measured in a limited number of patients may
lead to over-fitting issues. Hence, inflated variances result
in non-significant associations. In order to circumvent
these problems and to simplify the interpretation, geno-
typic mutations are summarised in a so-called genotypic
score. This score is the sum of observed resistance muta-
tions at baseline for the given drug in a given patient. The
mutations composing the score are selected by different
strategies [5,6]. The drawbacks of this analysis are that a
preselection of mutations is required and that every muta-
tion has the same weighting. Alternative strategies such as
principal component analysis (PCA) and partial least
square (PLS) regression have been suggested for the sake
of size reduction of correlated predictors [5,7-9] and may
present advantages to improve the description of associa-
tions between mutations. The two techniques do not lead
to a selection of mutations but to a different weighting of
each mutation presented in the dataset. We aimed at com-
paring these two strategies with the usual construction of
a genotypic score using data from an existing study evalu-
ating the impact of protease mutations on the virological




The Zephir study was designed to investigate the impact of
baseline protease genotypic mutations in HIV-1 infected
PI-experienced patients on virological response. All
patients had baseline HIV-1 RNA levels >1.7 log10 copies/
mL and switched to a ritonavir-boosted fosamprenavir-
based HAART [10]. Patients included were followed at the
Bordeaux University hospital and at four other public hos-
pitals in Aquitaine, south western France, all participating
to the ANRS CO3 Aquitaine Cohort. We used a subset of
87 patients with a complete baseline genotype and
plasma HIV-1 RNA available at baseline and at week 12.
Virological failure was defined as a HIV-1 RNA ≥400 cop-
ies/mL and <1 log10 copies/mL decrease of HIV-1 RNA
between baseline and week 12 (virological success: HIV-1
RNA <400 copies/mL or ≥1 log10 copies/mL reduction). A
mutation was defined as a difference between the amino
acid sequence of the studied virus and the wild type
(HXB2) virus. In total, we created 69 dummy variables
(69 mutations among the 99 possible protease mutations
were encountered at least once).
Statistical analysis
Construction of a genotypic score
The genotypic score was created in two steps. The first step
considered mutations with prevalences ≥10% and ≤90%
[5] to assess their association with virological failure.
Mutations associated with a p-value ≥ 0.01 (univariable
logistic regression) were selected. Second, the backwards
procedure selected the combination with the strongest
association with virological response [6]. These m selected
mutations were used to calculate the first genotypic score
for each patient. For instance, a first set contains the six
mutations V32, I47, I50, V77, I84 and L90. The score is
defined as S = IV32 + II47 + II50 + IV77 + II84 + IL90 (S varying
from 0 to 6). During the backwards selection procedure
every mutation was removed one by one and all combina-
tions of (m-1) mutations were investigated. The Cochran-
Armitage test for linear trends in proportions was used to
compare the probability of virological failure in patients
having none to (m-1) mutations [11]. The combination
providing the lowest p-value was kept and the procedure
was repeated with all combinations of (m-2) mutations.
The procedure stopped when removal of a mutation did
not result in a lower p-value.
We performed 200 bootstrap samples from the original
data set to analyze the variability in mutations' selection.
We assumed that variability in the selection of mutations
due to the restricted sample size might essentially play aBMC Medical Research Methodology 2008, 8:68 http://www.biomedcentral.com/1471-2288/8/68
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role in the first selection step. Therefore, a bootstrap anal-
ysis was performed only to the first selection criteria. In
each sample the prevalence of each mutation was calcu-
lated. A univariable logistic regression was performed to
determine the association of each mutation with virologic
failure in each sample. Then we calculated the frequencies
of selection of each mutation in the 200 bootstrap sam-
ples under the conditions mentioned above (prevalence
between 10% and 90% and a p-value < 0.01 in univaria-
ble analysis).
Principal component analysis (PCA)
Each principal component is a linear combination of the
original variables, with coefficients equal to the eigenvec-
tors of the correlation or covariance matrix [7,9]. Principal
components analysis determines components which are
representing the variability of the mutations. The associa-
tion between the principal components and the response
variable was tested with the Wald test statistics of the esti-
mated regression coefficient related to the principal com-
ponents. We only tested principal components with an
eigenvalue >2 reflecting that ≥3% of the variability of the
mutations was explained. Any principal component was
kept when it was related to the virological response using
a logistic regression according to the Wald test.
Partial least square (PLS) regression
PLS regression is a technique widely used for dealing with
numerous correlated explanatory variables [8,12]. PLS
regression aims also at identifying components explaining
as much as possible the variance of the predictor variables.
These components are simultaneously correlated with the
response variable. Over-fitting issues were controlled with
a leave-one-out cross-validation during the construction
process. The number of factors chosen is usually the one
that minimizes the predicted residual sum of squares
(PRESS) [13].
Comparison
The probability of virological failure at week 12 was stud-
ied using a logistic regression model adjusted for either
the genotypic score or the principal components or the
PLS components as explanatory variables. The perform-
ance of each strategy was compared using the cross-vali-
dated AUC [7,8]. We used 5-fold cross-validation. We split
the dataset in five equal parts. That way we selected five
times a dataset with 1/5 of the patients as 'validation set'
and the remaining 4/5 of the patients served as 'test set'.
In the test set, we determined i) the genotypic score ii) the
principal components and iii) the PLS components. The
selected mutations were then used to calculate the geno-
typic score for the patients included in the validation set.
The weights for each mutation derived by PCA and PLS
were applied to calculate the score of the principal com-
ponent and the PLS component respectively for the
patients of the validation set. For each validation set the
AUC under the ROC curve was calculated by means of a
logistic regression for the three different methods. Thus,
we obtained for each method 5 AUCs and the cross-vali-
dated AUC was calculated as the mean of these 5 AUCs.
This approach allows to avoid over-fitting because the per-
formance of the methods is tested in a subset of patients
that were not used to determine the genotypic score and
the weights of mutations in the PCA and PLS compo-
nents.
Statistical analyses were performed using SAS® version 9.1
software (SAS Institute, Inc., Cary, NC). We used the pro-
cedures PROC PRINCOMP for principal component anal-
ysis and PROC PLS for partial least square regression.
Principal components and PLS components were deter-
mined considering all mutations being present in at least
one patient.
Results
Study population characteristics have been reported
before [10]. We used a subset of 87 patients with a com-
plete baseline genotype and plasma HIV-1 RNA available
at baseline and at week 12. Virological failure was
observed in 46 (53%) patients at week 12. Mutations at
codon 63 had the highest prevalence in this population
80% followed by mutations at codons 10 (58%), 71
(51%), 46 (47%), 54 (47%), 37 (47%), 35 (41%), 82
(40%) and 90 (40%). Mutations at codons 11, 12, 13, 14,
15, 19, 20, 32, 33, 34, 36, 41, 43, 47, 55, 57, 60, 61, 62,
64, 69, 72, 73, 77, 84, 89 and 93 had prevalences between
10% and 40%. Mutations at codons 10, 46, 54, 82 and 90
showed the highest association with virological failure in
univariable analysis (p < 10-5). All patients with virologi-
cal failure presented a mutation at codon 84.
Genotypic score
Among mutations occurring in more than 10% and less
than 90% of the patients, 27, 18 and 11 mutations were
selected according to p-value thresholds of < 0.25, < 0.05
and < 0.01, respectively. The backward selection proce-
dure using the Cochrane Armitage trend test was started
with the 11 mutations (10, 33, 36, 46, 54, 62, 71, 73, 82,
84, 90) selected with the most restrictive criteria (p < 0.01)
to avoid computational issues. The stability of this selec-
tion step was checked on 200 bootstrap samples. Seven
(10:100%, 46: 100%, 54: 100%, 71: 95.5%, 82: 97%, 84:
100%, 90: 96%) of the 11 mutations were selected in over
90% of the samples. The other four mutations were
selected between 50% and 90% (33: 88%, 36: 68%, 62:
50%, 73: 68.5%). Mutations not included in the IAS list
[14] were in general not selected in the bootstrap samples
(exceptions: 19: 36.5%, 37: 19% and 41: 19%). This addi-
tional bootstrap analysis confirmed that mutations
known to be associated with virological failure were cho-BMC Medical Research Methodology 2008, 8:68 http://www.biomedcentral.com/1471-2288/8/68
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sen for further steps. Mutations (also known as polymor-
phisms) that also occur occasionally in untreated patients,
thus generally without any relation to antiretroviral treat-
ment, were chosen in less than 3% of the bootstrap sam-
ples.
During the backward selection procedure the following
six mutations 10, 36, 46, 62, 84, and 90 were selected for
the calculation of a genotypic score. The genotypic score
calculated with these six mutations was significantly asso-
ciated with virological failure (OR = 4.1 for a difference of
one mutation, CI95% [2.4; 7.0]; p < 10-4; cross-validated
OR = 4.9).
Principal component analysis
The first and second principal components explained
11% and 6% of mutations variability. Principal compo-
nents accounted for a small variability overall. Therefore,
their interpretation was difficult. The correlation of the
mutations amongst them and to the principal compo-
nents allowed identifying some clusters as for example
mutations 10, 46 and 90 or mutations 32 and 47 already
known to be associated together (figure 1). Figure 2 repre-
sents the relative weight of each mutation in the dataset to
calculate the first principal component. The relative
weight of each mutation to calculate the PCA 'score'
ranged between 0% (e.g. mutation at codon 22) and 4.3%
(e.g. mutations at codons 10 and 54). The sum of the rel-
ative weights of mutations represented in the IAS list was
70%, meaning that mutations of the IAS list contributed
the most to calculate the first principal component. The
mutations at the following six positions 10, 33, 46, 54, 82
and 90 contributed mostly to the first component (figure
2). Among others, mutations at positions 77, 88 and 30
contributed with a negative scoring coefficient to the first
component, meaning that the presence of such mutation
would decrease the value of the score. Medians of the first
and the second principal component were -0.10 (IQR: -
0.5–0.84) and 0 (IQR: -0.53–0.40), respectively. The first
principal component was significantly associated with
virological failure with an OR of 11.9 (CI95% [4.8; 29.7], p
< 10-4) for a difference of one unit whereas the second was
not OR = 1.1 (CI95% 0.7; 1.7, p = 0.62).
Partial least Square
One PLS component was chosen according to the PRESS
criterion. This component explained 11% of the variabil-
ity of the mutations and 60% of the variability of the
response variable. The median of the first PLS component
was -0.17 (IQR: -2.69–2.64). This PLS component was sig-
nificantly associated with virological failure OR = 2.6
(CI95%1.8; 3.9 p < 10-4). Figure 3 represents the relative
weight of each mutation in the dataset to calculate the first
PLS component. Mutations at positions 10, 46, 54, 82, 84,
and 90 had the highest contribution to the calculation of
the first component (figure 3). Negative weight for the cal-
culation of the first PLS component was amongst others
given by mutations 77, 30 and 48. Mutation at codon 69
contributed with the smallest relative weight (0.03%) and
mutation at codon 10 with the highest (4.7%). The con-
tribution of mutations included into the IAS list was 69%
(i.e. the sum of relative weights). Thus, mutations already
known to be associated with virological failure were given
more weight than polymorphisms (mutations that also
occur occasionally generally without association to
antiretroviral treatment).
Comparison
We compared the results of the PCA and PLS with the
results obtained using the classical strategy to build a gen-
otypic score. Mutations 10, 46 and 90 were found among
the six mutations contributing with the highest weight for
the calculation of the first PC, the first PLS component
and were selected for the genotypic score. Major muta-
tions 54 and 82, which were found among the mutations
Mutations on the first and second principal components Figure 1
Mutations on the first and second principal compo-
nents. All mutations having prevalences different from 0 are 
depicted. The wild type amino acid is cited before the codon 
of the mutation. Interpretation:  PC1: First principal compo-
nent (representing 11% of the variability), PC2: Second prin-
cipal component (representing 6% of the variability). 
Mutations are represented by the component when they are 
close to the corresponding axis. When two mutations are far 
from the center, then, if they are: i) Close to each other, they 
are significantly positively correlated; ii) If they are in a rec-
tangular position, they are not correlated; iii) If they are on 
the opposite side of the center, then they are negatively cor-
related. When the mutations are close to the center, it 
means that some information is carried on other axes.BMC Medical Research Methodology 2008, 8:68 http://www.biomedcentral.com/1471-2288/8/68
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with the highest association to virological failure in uni-
variable analysis, were also found among the six muta-
tions contributing with the highest weight for the
calculation of the first PC and the first PLS component. In
contrast, these two mutations were eliminated from the
score during the backward selection procedure (figure 4).
Therefore, one first advantage of methods based on PCA
and PLS is that they helped in reducing the number of pre-
dictors without neglecting mutations that could play a sig-
nificant role.
We compared the performance of these three methods
with the area under the ROC curve. The cross-validated
AUCs for the PCA, PLS and genotypic score were 0.880,
0.868 and 0.863, respectively. The model with the first
principal component slightly outperformed the model
with one PLS component. The predictive quality of the
genotypic score was slightly lower than the two AUCs
obtained for PCA and PLS but still showed a very good
performance.
To compare the methods in an illustrative way we used a
patient presenting the following 21 protease gene muta-
tions at baseline: mutations at positions 33, 54, 82, 90
defined as major, mutations at positions 10, 13, 20, 35, 36
43, 53, 60, 63, 64, 74 defined as minor and mutations at
positions 14, 15, 19, 37, 67, 98 defined as polymor-
phisms. Virological failure was observed for this patient.
The genotypic score was S = I10+I36+I90 = 3 and the proba-
bility of virological failure was 77% using this score. The
main difference between the genotypic score and the prin-
cipal component value or the PLS component value is that
with the latter methods we can take in consideration the
fact that the patient has 21 protease gene mutations and
give them different weights. For instance, the relative
weights for mutations 10, 36, 90 were 4.4%, 2.2%, 4.1%
and 4.7%, 2.4%, 4.4% for the PCA and PLS 'score', respec-
tively (figure 2 and 3). The predicted probability of viro-
logical failure was 94% and 96% using the PC "score" and
the PLS "score", respectively.
Discussion
We investigated PCA and PLS regression to analyse associ-
ations between baseline protease mutations and virologi-
cal failure. PCA and PLS are easily applicable because they
are implemented in standard statistical analyses programs
such as SAS (SAS Institute, Inc., Cary, NC).
Relative weights of each mutation to calculate the 'score' of the first principal component Figure 2
Relative weights of each mutation to calculate the 'score' of the first principal component. Black line: separation 
of mutations represented in the IAS list [14] and polymorphisms.BMC Medical Research Methodology 2008, 8:68 http://www.biomedcentral.com/1471-2288/8/68
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Relative weights of each mutation to calculate the 'score' of the first PLS component Figure 3
Relative weights of each mutation to calculate the 'score' of the first PLS component. Black line: separation of 
mutations represented in the IAS list [14] and polymorphisms.
Codons of mutations taken into consideration by the presented methods to predict virological (Codons at which polymor- phisms occur are not depicted) Figure 4
Codons of mutations taken into consideration by the presented methods to predict virological failure(Codons 
at which polymorphisms occur are not depicted). The IAS mutation list shows all codons which have been described to 
be related with resistance to any of the protease inhibitors. Black boxes: Codons where major mutations occur.BMC Medical Research Methodology 2008, 8:68 http://www.biomedcentral.com/1471-2288/8/68
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We compared these two techniques with the construction
of a genotypic score because they allow considering each
mutation with a different weight. The objective of PCA is
to find a set of new "latent variables" in form of a linear
transformation of the original predictors. The properties
of these latent variables are that they are uncorrelated and
that they account for as much of the variance of the pre-
dictor variables as possible. PCA has been recently used to
determine clusters of mutations in patients that were
treated with at least one PI [15] and to predict the pheno-
typic fold change from genotypic information [16]. PLS
regression reduces also a set of predictor variables to a set
of uncorrelated "latent variables", the so-called PLS com-
ponents. The main difference between the two techniques
is that PLS also considers the strength of each mutation
effect on the virological response to construct the compo-
nents. Hence, these two methods can help solving the
issues of the high number of predictors and their different
effects. They may also help in describing the relationship
between mutations by detecting potential groups of muta-
tions. PLS was mentioned to be a useful analysing strategy
for genotypic mutation data [5] but neither applications
nor comparisons had been published yet.
In this study population, these two methods were able to
identify some mutations that were expected to contribute
with higher weights to virologic failure (e.g. mutations at
codons 10, 82 and 90 which contribute to resistance to at
least 7 of the 8 currently used PIs [5]). Furthermore,
known clusters of mutations could be described. Recent
papers including co-variation analysis [15,17-19] found
some correlated pairs and clusters which are associated
with a specific treatment. Two of them used PCA to visu-
alise correlations of mutations. We identified some clus-
ters of mutations, e.g. mutations at codons 10, 46, and 90
and at codons 33, 46, 54 and 82, which were also found
to be correlated with each other. Mutations 32 and 47 had
the highest correlation coefficient (r = 0.78) in this popu-
lation and are known to be key mutations for amprenavir
[20] and lopinavir [14]. The cluster of mutations at posi-
tions 10, 46, 90 [19] and a high correlation between 32
and 47 were also determined by Wu et al and Kagan et al
[19,21]. The mutations 10, 33, 46, 54, 71, 82, 84 and 90
are separated from all other mutations by the PCA and are
contributing with the highest weight to calculate this com-
ponent. The cluster 10, 46, 54, 71, 90 was recently
described [17] to appear under lopinavir treatment and
these mutations are also related to amprenavir-resistance
[22]. We found that PCA had indeed detected this latter
cluster in our patient's population previously treated by
lopinavir or amprenavir (25% and 32% of the patients,
respectively). Furthermore, the fact that the principal
component was related to virological response highlights
that PCA can detect mutation clusters on the way to lopi-
navir and fosamprenavir resistance although principal
component analysis did not consider the virologic
response for the construction of the component. As men-
tioned above, PLS searches latent variables but takes into
account the response variable. Consequently one might
expect differences for the distribution of the weights given
by the mutations. Actually, the mutations found to con-
tribute the highest weight on the PLS component are
almost the same. Among the six mutations contributing
with the highest weight, mutations at codons 10, 46, 54
82 and 90 were found for the principal component and
the PLS component. Mutation at codon 33 was found on
the principal component, while mutation 84 was found
on the PLS component. In addition, the mutations which
contributed with a higher weight for the calculation of the
first principal and first PLS components are those which
showed the highest association with virological response
in univariable analysis. In conclusion, the weightings of
the mutations found were consistent across these alterna-
tive strategies. A possible explanation is that the patients
were mainly pre-treated with two PIs known to induce
similar mutation patterns than fosamprenavir. In other
cases, PLS might outperform PCA when a drug induces
completely different mutations since the virological
response is considered during the construction of the
component.
The above presented example (patient presenting 21 pro-
tease gene mutations) highlights the advantage of taking
into account all mutations and giving them different
weights by either PCA or PLS. This results in a better pre-
diction of virological failure. After cross-validation the
first principal component and the first PLS component
only slightly outperformed the genotypic score in the pre-
diction ability. However, it has to be stated that the cross-
validated AUCs showed no clinical relevant difference. In
this study population this might partly be explained by
the fact that there was an explicit subset of mutations
strongly associated with virological failure. This was also
substantiated by the bootstrap analyses in which four of
the six mutations remaining in the final genotypic score
had been selected in over 95% of the bootstrap samples.
This clear separation between mutations associated with
virological failure from those which are not, could have
facilitated the detection of a predictive subset using the
classical strategy to construct a genotypic score.
One of the reasons to apply PCA and PLS analyses to these
kind of data was that these approaches do not need a pre-
selection of variables (i.e. mutations) as they are summa-
rized in predictors. Hence, all mutations can be consid-
ered even when they are present in a small proportion of
patients. Among others, the attempt to study these
approaches was to study whether considering all muta-
tions has an advantage and if mutations known to be
associated with virologic failure are given higher weights.BMC Medical Research Methodology 2008, 8:68 http://www.biomedcentral.com/1471-2288/8/68
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However, the slightly better performance of the alterna-
tive approaches may be simply linked with the use of a
larger amount of information. This was the minimum
expected gain of these approaches compared to the usual
one.
Therefore, it would be very helpful to study the perform-
ance of PCA and PLS in other, potentially bigger, trials
considering other antiretroviral regimen/patients.
Conclusion
PCA and PLS regression were helpful in describing the
association between mutations and to detect mutation
clusters. PCA and PLS showed a good performance but
their predictive ability was not clinically superior to that
of the genotypic score.
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